Verastem Director Richard Aldrich Purchases 1,000 Shares (VSTM)
Verastem (NASDAQ:VSTM) Director Richard Aldrich acquired 1,000 shares of Verastem stock in a transaction that occurred on Monday, September 30th. The stock was purchased at an average cost of $12.55 per share, with a total value of $12,550.00. Following the completion of the purchase, the director now directly owns 407,142 shares in the company, valued at approximately $5,109,632. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Several analysts have recently commented on the stock. Analysts at UBS AG raised their price target on shares of Verastem (NASDAQ:VSTM) from $20.00 to $30.00 in a research note to investors on Wednesday, August 7th. They now have a “buy” rating on the stock. Separately, analysts at Jefferies Group initiated coverage on shares of Verastem (NASDAQ:VSTM) in a research note to investors on Monday, July 29th. They set a “buy” rating and a $21.00 price target on the stock. Finally, analysts at Roth Capital raised their price target on shares of Verastem (NASDAQ:VSTM) from $23.00 to $29.00 in a research note to investors on Monday, July 15th. They now have a “buy” rating on the stock. Eight investment analysts have rated the stock with a buy rating, The company currently has a consensus rating of “Buy” and a consensus target price of $22.11.
Verastem (NASDAQ:VSTM) traded down 2.05% on Monday, hitting $12.45. 125,792 shares of the company’s stock traded hands. Verastem has a one year low of $6.25 and a one year high of $18.82. The stock’s 50-day moving average is $13.88 and its 200-day moving average is $12.01. The company’s market cap is $318.6 million.
Verastem (NASDAQ:VSTM) last announced its earnings results on Tuesday, August 13th. The company reported ($0.49) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.41) by $0.08. On average, analysts predict that Verastem will post $-1.75 earnings per share for the current fiscal year.
Verastem, Inc is a United States-based biopharmaceutical company. The Company focuses on discovering and developing drugs to treat cancer by targeting cancer stem cells, which are an underlying cause of tumor recurrence and metastasis.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.